Empire Genomics Licenses Biomarker from Emory University for Multiple Myeloma CDx | GenomeWeb

NEW YORK (GenomeWeb News) – Empire Genomics said today that it has acquired the exclusive license to a genomic biomarker from Emory University for the development of a molecular diagnostic test for determining which therapies may be most suitable for specific patients with multiple myeloma.

A phase II biomarker-driven clinical trial is being conducted using the technology to validate its ability to predict outcomes of new generations of drugs for the blood cell cancer, Empire Genomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.